Breaking News, Collaborations & Alliances, Trials & Filings

Trials & Filings in Brief: Jan. 15, 2014

AbbVie, Antares, Elite, Galectin, La Jolla

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase I Galectin drug in early test against melanoma . . . read more Phase II La Jolla launches extension study . . . read more Phase III AbbVie begins triple-negative breast cancer trial . . . read more 505(b)2 Dosing begins for Elite bioequivalence study . . . read more Launches Antares releases subcutaneous MTX . . . read more...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters